Nature cancer · 2021

Functional antibody and T cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE study.

СтатьяПоддержка NIH: внешняя программаПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен

Обработка статьи · этапы, ошибки и управление

Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Fendler Annika, Au Lewis, Shepherd Scott T C, Byrne Fiona, Cerrone Maddalena, Boos Laura Amanda, Rzeniewicz Karolina, Gordon William, Shum Benjamin, Gerard Camille L, Ward Barry, Xie Wenyi, Schmitt Andreas M, Joharatnam-Hogan Nalinie, Cornish Georgina H, Pule Martin, Mekkaoui Leila, Ng Kevin W, Carlyle Eleanor, Edmonds Kim, Rosario Lyra Del, Sarker Sarah, Lingard Karla, Mangwende Mary, Holt Lucy, Ahmod Hamid, Stone Richard, Gomes Camila, Flynn Helen R, Agua-Doce Ana, Hobson Philip, Caidan Simon, Howell Michael, Wu Mary, Goldstone Robert, Crawford Margaret, Cubitt Laura, Patel Harshil, Gavrielides Mike, Nye Emma, Snijders Ambrosius P, MacRae James I, Nicod Jerome, Gronthoud Firza, Shea Robyn L, Messiou Christina, Cunningham David, Chau Ian, Starling Naureen, Turner Nicholas, Welsh Liam, van As Nicholas, Jones Robin L, Droney Joanne, Banerjee Susana, Tatham Kate C, Jhanji Shaman, O'Brien Mary, Curtis Olivia, Harrington Kevin, Bhide Shreerang, Bazin Jessica, Robinson Anna, Stephenson Clemency, Slattery Tim, Khan Yasir, Tippu Zayd, Leslie Isla, Gennatas Spyridon, Okines Alicia, Reid Alison, Young Kate, Furness Andrew J S, Pickering Lisa, Gandhi Sonia, Gamblin Steve, Swanton Charles, Crick COVID-19 Consortium, Nicholson Emma, Kumar Sacheen, Yousaf Nadia, Wilkinson Katalin A, Swerdlow Anthony, Harvey Ruth, Kassiotis George, Larkin James, Wilkinson Robert J, Turajlic Samra, CAPTURE consortium

Аннотация

Patients with cancer have higher COVID-19 morbidity and mortality. Here we present the prospective CAPTURE study, integrating longitudinal immune profiling with clinical annotation. Of 357 patients with cancer, 118 were SARS-CoV-2 positive, 94 were symptomatic and 2 died of COVID-19. In this cohort, 83% patients had S1-reactive antibodies and 82% had neutralizing antibodies against wild type SARS-CoV-2, whereas neutralizing antibody titers against the Alpha, Beta and Delta variants were substantially reduced. S1-reactive antibody levels decreased in 13% of patients, whereas neutralizing antibody titers remained stable for up to 329 days. Patients also had detectable SARS-CoV-2-specific T cells and CD4+ responses correlating with S1-reactive antibody levels, although patients with hematological malignancies had impaired immune responses that were disease and treatment specific, but presented compensatory cellular responses, further supported by clinical recovery in all but one patient. Overall, these findings advance the understanding of the nature and duration of the immune response to SARS-CoV-2 in patients with cancer.

Предметные рубрики MeSH

Adolescent Adult Aged Aged, 80 and over Antibodies, Neutralizing Antibodies, Viral COVID-19 Female Follow-Up Studies Humans Immunity, Cellular Male Middle Aged Neoplasms Prospective Studies SARS-CoV-2 Spike Glycoprotein, Coronavirus T-Lymphocytes Young Adult

Functional antibody and T cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE study.

Ошибки и ограничения

Аннотация

Предметные рубрики MeSH